Role of Apo2L/TRAIL and Bcl-2-family proteins apoptosis of multiple myeloma

Leukemia and Lymphoma

Volumn 44, Issue 7, 2003, Pages 1209-1214

  Chen, Quan ^a   Ray, Subrata ^a   Hussein, Muhamad A ^b   Srkalovic, Gordan ^b   Almasan, Alexandru ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Apo2L TRAIL; Apoptosis; Bcl 2 family proteins; Interferon; Multiple myeloma

Indexed keywords

ALPHA INTERFERON; ARSENIC TRIOXIDE; BETA INTERFERON; CASPASE; CD40 ANTIGEN; DACTINOMYCIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HEXAMETHYLENEBISACETAMIDE; HYDROGEN PEROXIDE; INTERLEUKIN 6; MELPHALAN; MITOXANTRONE; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN P53; STAT PROTEIN; THALIDOMIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; CANCER CELL CULTURE; CELL DEATH; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG RESISTANCE; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; MULTIGENE FAMILY; MULTIPLE MYELOMA; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN FAMILY; RECEPTOR BINDING; REVIEW; TUMOR SUPPRESSOR GENE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038662972     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000068052     Document Type: Review

References (67)

1. Hussein, M.A., Juturi, J.V. and Lieberman, I. (2002) "Multiple myeloma: present and future", Curr. Opin. Oncol. 14, 31-35.
2. Puthier, D., Pellat-Deceunynck, C., Barille, S., Robillard, N., Rapp, M.J., Juge-Morineau, N., Harousseau, J.L., Bataille, R. and Amiot, M. (1999) "Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy", Leukemia 13, 289-294.
3. Wang, X. (2001) "The expanding role of mitochondria in apoptosis", Genes Dev. 15, 2922-2933.
4. Chen, Q., Gong, B., Mahmoud-Ahmed, A., Zhou, A., Hsi, E.D., Hussein, M. and Almasan, A. (2001) "Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon- induced apoptosis in multiple myeloma", Blood 98, 2183-2192.
5. Ashkenazi, A. (2002) "Targeting death and decoy receptors of the tumour-necrosis factor superfamily", Nat. Rev. Cancer 2, 420-430.
6. Kischkel, F.C., Lawrence, D.A., Chuntharapai, A., Schow, P., Kim, K.J. and Ashkenazi, A. (2000) "Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5", Immunity 12, 611-620.
7. Luo, X., Budihardjo, I., Zou, H., Slaughter, C. and Wang, X. (1998) "Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors", Cell 94, 481-490.
8. Gong, B. and Almasan, A. (2000) "Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells", Cancer Res. 60, 5754-5760.
9. Chen, Q., Chai, Y.-C., Mazumder, S., Jiang, C., Macklis, R.M., Chisolm, G.M. and Almasan, A. (2002) "The late increase in intracellular free radical oxygen species during apoptosis is dependent on cytochrome c release caused by caspase-mediated feedback amplification", Cell Death Diff. 10(3), 1-12.
10. Cory, S. and Adams, J.M. (2002) "The bcl2 family: regulators of the cellular life-or-death switch", Nat. Rev. Cancer 2, 647-656.
11. Chinnaiyan, A., Orth, K., O'Rourke, K., Duan, H., Poirier, G. and Dixit, V. (1996) "Molecular ordering of the cell death pathway. Bcl-2 and Bcl-xL function upstream of the CED-3-like apoptotic proteases", J. Biol. Chem. 271, 4573-4576.
12. Chen, Q., Gong, B. and Almasan, A. (2000) "Distinct stages of cytochrome c release from mitochondria: evidence for a feedback amplification loop linking caspase activation to mitochondrial dysfunction in genotoxic stress induced apoptosis", Cell Death Differ. 7, 227-233.
13. Pitti, R.M., Marsters, S.A., Ruppert, S., Donahue, C.J., Moore, A. and Ashkenazi, A. (1996) "Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family", J. Biol. Chem. 271, 12687-12690.
14. Wiley, S.R., Schooley, K., Smolak, P.J., Din, W.S., Huang, C.P., Nicholl, J.K., Sutherland, G.R., Smith, T.D., Rauch, C., Smith, C.A. and Goodwin, R.G. (1995) "Identification and characterization of a new member of the TNF family that induces apoptosis", Immunity 3, 673-682.
15. Ashkenazi, A., Pai, R.C., Fong, S., Leung, S., Lawrence, D.A., Marsters, S.A., Blackie, C., Chang, L., McMurtrey, A.E., Hebert, A., DeForge, L., Koumenis, I.L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z. and Schwall, R.H. (1999) "Safety and antitumor activity of recombinant soluble Apo2 ligand", J. Clin. Investig. 104, 155-162.
16. Walczak, H., Miller, R.E., Ariail, K., Glimak, B., Griffith, T.S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., Smith, C., Smolak, P., Goodwin, R.G., Rauch, C.T., Schuh, J.C. and Lynch, D.H. (1999) "Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo", Nat. Med. 5, 157-163.
17. LeBanc, H., Lawrence, D., Varfolomeev, E., Totpal, K., Morlan, J., Schow, P., Fong, S., Schwall, R., Sinicropi, D. and Ashkenazi, A. (2002) "Tumor cell resistance to death receptor induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax", Nat. Med. 8, 274-278.
18. Sangfelt, O., Erickson, S., Castro, J., Heiden, T., Einhorn, S. and Grander, D. (1997) "Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines", Cell Growth Differ. 8, 343-352.
19. Minami, R., Muta, K., Ilseung, C., Abe, Y., Nishimura, J. and Nawata, H. (2000) "Interleukin-6 sensitizes multiple myeloma cell lines for apoptosis induced by interferon-alpha", Exp. Hematol. 28, 244-255.
20. Gong, B. and Almasan, A. (2000) "Genomic organization and transcriptional regulation of the human Apo2L/TRAIL gene", Biochem. Biophys. Res. Commun. 278, 747-752.
21. Kumar-Sinha, C., Varambally, S., Sreekumar, A. and Chinnaiyan, A.M. (2002) "Molecular cross-talk between the TRAIL and interferon signaling pathways", J. Biol. Chem. 277, 575-585.
22. Gazitt, Y. (1999) "TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells", Leukemia 13, 1817-1824.
23. Mitsiades, C.S., Treon, S.P., Mitsiades, N., Shima, Y., Richardson, P., Schlossman, R., Hideshima, T. and Anderson, K.C. (2001) "TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications", Blood 98, 795-804.
24. Lincz, L.F., Yeh, T.X. and Spencer, A. (2001) "TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy", Leukemia 15, 1650-1657.
25. Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., Hooley, J., Sherwood, S., Pai, R., Leung, S., Khan, L., Gliniak, B., Bussiere, J., Smith, C.A., Strom, S.S., Kelley, S., Fox, J.A., Thomas, D. and Ashkenazi, A. (2001) "Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions", Nat. Med. 7, 383-385.
26. Liu, Q., El-Deiry, W.S. and Gazitt, Y. (2001) "Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines", Exp. Hematol. 29, 962-970.
27. Mitsiades, N., Mitsiades, C.S., Poulaki, V., Anderson, K.C. and Treon, S.P. (2002) "Intracellular regulation of tumor necrosis factor-related apoptosis- inducing ligand-induced apoptosis in human multiple myeloma cells", Blood 99, 2162-2171.
28. Jazirehi, A.R., Ng, C.P., Gan, X.H., Schiller, G. and Bonavida, B. (2001) "Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis- inducing ligand-mediated (TRAIL) apoptosis", Clin. Cancer Res. 7, 3874-3883.
29. Jourdan, M., De Vos, J., Mechti, N. and Klein, B. (2000) "Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1", Cell Death Differ. 7, 1244-1252.
30. Catlett-Falcone, R., Landowski, T.H., Oshiro, M.M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernandez-Luna, J.L., Nunez, G., Dalton, W.S. and Jove, R. (1999) "Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells", Immunity 10, 105-115.
31. Puthier, D., Thabard, W., Rapp, M., Etrillard, M., Harousseau, J., Bataille, R. and Amiot, M. (2001) "Interferon alpha extends the survival of human myeloma cells through an upregulation of the Mcl-1 anti-apoptotic molecule", Br. J. Haematol. 112, 358-363.
32. Mitsiades, N., Mitsiades, C.S., Poulaki, V., Chauhan, D., Richardson, P.G., Hideshima, T., Munshi, N.C., Treon, S.P. and Anderson, K.C. (2002) "Apoptotic signaling induced by immuno-modulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications", Blood 99, 4525-4530.
33. Mitsiades, N., Mitsiades, C.S., Poulaki, V., Chauhan, D., Richardson, P.G., Hideshima, T., Munshi, N., Treon, S.P. and Anderson, K.C. (2002) "Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications", Blood 99, 4079-4086.
34. Akagi, T., Kondo, E. and Yoshino, T. (1994) "Expression of Bcl-2 protein and Bcl-2 mRNA in normal and neoplastic lymphoid tissues", Leuk. Lymphoma 13, 81-87.
35. Pettersson, M., Jernberg-Wiklund, H., Larsson, L.G., Sundstrom, C., Givol, I., Tsujimoto, Y. and Nilsson, K. (1992) "Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells", Blood 79, 495-502.
36. Gazitt, Y., Fey, V., Thomas, C. and Alvarez, R. (1998) "Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells", Int. J. Oncol. 13, 397-405.
37. Miguel-Garcia, A., Orero, T., Matutes, E., Carbonell, F., Miguel-Sosa, A., Linares, M., Tarin, F., Herrera, M., Garcia-Talavera, J. and Carbonell-Ramon, F. (1998) "bcl-2 expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: a comparative study", Haematologica 83, 298-304.
38. Gazitt, Y., Shaughnessy, P. and Montgomery, W. (1999) "Apoptosis-induced by TRAIL AND TNF-alpha in human multiple myeloma cells is not blocked by BCL-2", Cytokine 11, 1010-1019.
39. Derenne, S., Monia, B., Dean, N.M., Taylor, J.K., Rapp, M.J., Harousseau, J.L., Bataille, R. and Amiot, M. (2002) "Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells", Blood 100, 194-199.
40. Takeda, K., Smyth, M.J., Cretney, E., Hayakawa, Y., Kayagaki, N., Yagita, H. and Okumura, K. (2002) "Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development", J. Exp. Med. 195, 161-169.
41. Cretney, E., Takeda, K., Yagita, H., Glaccum, M., Peschon, J.J. and Smyth, M.J. (2002) "Increased susceptibility to tumor initiation and metastasis in TNF- related apoptosis-inducing ligand-deficient mice", J. Immunol. 168, 1356-1361.
42. Chauhan, D., Auclair, D., Robinson, E.K., Hideshima, T., Li, G., Podar, K., Gupta, D., Richardson, P., Schlossman, R.L., Krett, N., Chen, L.B., Munshi, N.C. and Anderson, K.C. (2002) "Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays", Oncogene 21, 1346-1358.
43. Ishitsuka, K., Hanada, S., Uozumi, K., Utsunomiya, A. and Arima, T. (2000) "Arsenic trioxide and the growth of human t-cell leukemia virus type i infected t-cell lines", Leuk. Lymphoma 37, 649-655.
44. Park, W.H., Seol, J.G., Kim, E.S., Hyun, J.M., Jung, CW., Lee, C.C., Kim, B.K. and Lee, Y.Y. (2000) "Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis", Cancer Res. 60, 3065-3071.
45. Hussein, M.A. (2001) "Arsenic trioxide: a new immunomodulatory agent in the management of multiple myeloma", Med. Oncol. 18, 239-242.
46. Alemany, M. and Levin, J. (2000) "The effects of arsenic-trioxide (As2O3) on human megakaryocytic leukemia cell lines. With a comparison of its effects on other cell lineages", Leuk. Lymphoma 38, 153-163.
47. Chauhan, D., Pandey, P., Ogata, A., Tech, G., Krett, N., Halgren, R., Rosen, S., Kufe, D., Kharbanda, S. and Anderson, K. (1997) "Cytochrome c-dependent and -independent induction of apoptosis in multiple myeloma cells", J. Biol. Chem. 272, 29995-29997.
48. Siegel, D.S., Zhang, X., Feinman, R., Teitz, T., Zelenetz, A., Richon, V.M., Rifkind, R.A., Marks, P.A. and Michaeli, J. (1998) "Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells", Proc. Natl Acad. Sci. USA 95, 162-166.
49. Tu, Y., Xu, F.H., Liu, J., Vescio, R., Berenson, J., Fady, C. and Lichtenstein, A. (1996) "Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide", Blood 88, 1805-1812.
50. Kawamura, C., Kizaki, M. and Ikeda, Y. (2002) "Bone morphogenetic protein (BMP)-2 induces apoptosis in human myeloma cells", Leak. Lymphoma 43, 635-639.
51. Tu, Y., Renner, S., Xu, F., Fleishman, A., Taylor, J., Weisz, J., Vescio, R., Rettig, M., Berenson, J., Krajewski, S., Reed, J.C. and Lichtenstein, A. (1998) "BCL-X expression in multiple myeloma: possible indicator of chemoresistance", Cancer Res. 58, 256-262.
52. Juturi, J., Bukowski, R.A., Bocock, K., Bloom, T., Finke, J. and Hussein, M.A. (2001) "High, intermittent dose of all-trans retinoic acid in combination with alpha-interferon for advanced multiple myeloma", Haematologica 86, 776-777.
53. Puthier, D., Derenne, S., Barille, S., Moreau, P., Harousseau, J.L., Bataille, R. and Amiot, M. (1999) "Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells", Br. J. Haematol. 107, 392-395.
54. Schwarze, M.M. and Hawley, R.G. (1995) "Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL", Cancer Res. 55, 2262-2265.
55. Zhang, B., Gojo, I. and Fenton, R.G. (2002) "Myeloid cell factor-1 is a critical survival factor for multiple myeloma", Blood 99, 1885-1893.
56. Gong, B. and Almasan, A. (1999) "Differential upregulation of p53-responsive genes by genotoxic stress in hematopoietic cells containing wild-type and mutant p53", Gene. Expr. 8, 197-206.
57. Almasan, A. (2000) "Cellular commitment to radiation-induced apoptosis", Radiat. Res. 153, 347-350.
58. Mazumder, S., Gong, B., Almasan, A. and Cyclin, E. (2000) "induction by genotoxic stress leads to apoptosis of hematopoietic cells", Oncogene 19, 2828-2835.
59. Mazumder, S., Chen, Q., Gong, B., Drazba, J.A., Buchsbaum, J.C. and Almasan, A. (2002) "Proteolyfic cleavage of cyclin E leads to inactivation of associated kinase activity and amplification of apoptosis in hematopoietic cells", Mol. Cell. Biol. 22, 2398-2409.
60. Secchiero, P., Gonelli, A., Celeghini, C., Mirandola, P., Guidotti, L., Visani, G., Capitani, S. and Zauli, G. (2001) "Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis-inducing ligand- mediated cytotoxicity on hematologic malignancies", Blood 98, 2220-2228.
61. Kanda, Y., Ara, C., Chizuka, A., Yamamoto, R., Hamaki, T., Suguro, M., Matsuyama, T., Takezako, N., Miwa, A., Tohma, J., Shirakawa, K., Yatomi, T., Nakamura, N., Hirai, H. and Togawa, A. (2001) "Lack of correlation between clinical characteristics and serum soluble Fas ligand levels in patient with multiple myeloma", Leuk. Lymphoma 40, 351-356.
62. Tong, A.W., Seamour, B., Chen, J., Su, D., Ordonez, G., Frase, L., Netto, G. and Stone, M.J. (2000) "CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells", Leuk. Lymphoma 36, 543-558.
63. Greil, R., Egle, A. and Villunger, A. (1998) "On the role and significance of Fas (Apo1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model", Leuk. Lymphoma 31, 477-490.
64. Hata, H., Matsuzaki, H., Takeya, M. and Takatsuki, K. (1996) "Fas/Apo-1 (CD95)-mediated and CD95-independent apoptosis of malignant plasma cells", Leuk. Lymphoma 24, 35-42.
65. Shima, Y., Nishimoto, N., Yoshizaki, K. and Kishimoto, T. (1996) "Fas antigen/APO-1 (CD95) expression on myeloma cells", Leuk. Lymphoma 23, 521-531.
66. Shiao, R.T., Miglietta, L., Khera, S.Y., Wolfson, A. and Freter, C.E. (1995) "Dexamethasone and suramin inhibit cell proliferation and interleukin-6- mediated immunoglobulin secretion in human lymphoid and multiple myeloma cell lines", Leuk. Lymphoma 17, 485-494.
67. Robertson, M.J., Manley, T.J., Pichert, G., Cameron, C., Cochran, K.J., Levine, H. and Ritz, J. (1995) "Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells", Leuk. Lymphoma 17, 51-61.